CanSino Biologics and AsymBio Collaborate to Harness mRNA Technology

In a recent strategic partnership, CanSino Biologics (Shanghai) Biotechnology Co., Ltd. and Shanghai AsymBio Biotechnology Co., Ltd. have joined forces to focus on the advancement of mRNA technology. This collaboration aims to drive innovation and facilitate the industrialization of mRNA technology. With CanSino Biologics's expertise as a leading company in the field of vaccines and their advanced mRNA technology platform, combined with AsymBio's capabilities in plasmids, mRNA, and LNP-based biopharmaceuticals, the two companies seek to accelerate the research and industrialization of mRNA technology.

CanSino Biologics (Shanghai) Biotechnology Co., Ltd., renowned for its leadership in the vaccine sector, has established a cutting-edge mRNA technology platform. The company possesses proprietary software for sequence optimization, enabling the identification of key stability factors and the optimization of antigen expression. With streamlined CMC processes, CanSino Biologics can expedite product development and swiftly transition scientific breakthroughs into industrial applications. Additionally, CanSino Biologics operates a state-of-the-art large-scale modern vaccine production base and has achieved significant innovation in the development of various novel vaccine products.

The strategic collaboration between CanSino Biologics and AsymBio will leverage the complementary strengths and resources of both companies. By fostering efficient communication channels and resource sharing, the partnership aims to unlock long-term benefits driven by trust, diversity, and cooperation. Together, the companies strive to achieve synergistic effects where the sum of their efforts surpasses individual contributions, particularly in areas such as cost management, service quality, user satisfaction, performance, and more. The ultimate goal is to accelerate the research and commercialization of related medications, ultimately benefiting patients worldwide.

CanSino Biologics Biotechnology remains committed to innovation-driven growth, actively seeking opportunities to create value. Leveraging its innovative mRNA technology platform, the company aims to enrich its pipeline of vaccine products, expanding its coverage in the field of infectious diseases. Furthermore, CanSino Biologics aspires to contribute to the improvement of global public health governance.

The collaboration between CanSino Biologics and AsymBio represents a significant milestone in the advancement of mRNA technology. By combining their expertise and resources, the two companies are poised to make significant strides in research, development, and commercialization. This partnership not only demonstrates the power of collaboration but also highlights their shared commitment to driving innovation in the pharmaceutical industry. As the world continues to face health challenges, this collaboration holds the potential to bring about groundbreaking solutions that will benefit patients on a global scale.